TACTI-003: A RANDOMIZED PHASE IIb STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB AS FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA

Background Eftilagimod alpha (efti) is a soluble LAG-3 protein targeting a subset of MHC class II molecules that mediate antigen-presenting cell (APC) and then CD8 T-cell activation. Data from a non-randomized, phase II trial of efti plus pembrolizumab (TACTI-002) showed encouraging antitumor activity and manageable safety when given as second-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). TACTI-003 (NCT04811027) is a multicenter, open-label, randomized phase IIb trial to investigate efti plus pembrolizumab in the first line setting for RM-HNSCC.

Methods A total of 154 patients (pts) are currently being recruited into two cohorts (A+B). In cohort A, pts with tumors that are CPS/C21 will be randomly assigned 1:1 to receive either efti (30 mg subcutaneously Q2W for initial 6 months, thereafter Q3W) plus pembrolizumab (400 mg intravenously Q6W) for up to two years or pembrolizumab alone. Randomization will be stratified by CPS (1-19 vs. ≥ 20) and ECOG PS (0 vs. 1). Pts with tumors that are CPS<1 will receive efti plus pembrolizumab (cohort B). Imaging will be performed every 9 weeks. The primary endpoint (EP) is the objective response rate (ORR) by RECIST1.1. Secondary EPs include overall survival, ORR according to iRECIST, time to and duration of response, disease control rate, progression-free survival, the occurrence of anti-efti-specific antibodies, safety, and quality of life. Exploratory endpoints comprise biomarkers.

Acknowledgements - We thank all the participating patients & their families.
- We thank the dedicated clinical trial investigators & their team members.
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA provided pembrolizumab for the study.
- Sponsored by Immutep.

Trial Registration The trial identifiers are IMP321-P022 (Sponsor code), Keynote-PNC-34 (MSD code), 2021-000055-39 (EudraCT) and NCT04811027 (ClinicalTrials.gov).

Ethics Approval This has been approved by relevant Competent Authorities, Ethics Committees, and Institutional Review Boards.